New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free
Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Friday, November 13, 2026

Back to the front page

TSOH Weekly Roundup (11/13/2026)

Tripadvisor’s CEO and CFO will depart after weak Q3 results, while Roblox’s CEO discusses AI and Berkshire repurchases $9.6 billion of stock.

TRIP $855M
TSOH Investment Research 2 clicks

From X

@aleabitoreddit

Serenity on X

For companies like $SIVE / $AAOI, the demand imbalance for lasers are so severe That even a 20-30% overall demand reduction from a hypothetical DC slowdown would likely not eliminate the shortage. We're seeing this before the next architectural shifts, where $NVDA Jensen Huang expects 15x optical volume for CPO scale-up. And as more hyperscalers commit to NPO as seen with $LITE new $5B UHP laser contracts. I'd argue this is more nuanced since I can't say the same for finished 800G/1.6T pluggables or lower end 70mW-100mW laser ranges that are currently bottlenecks. But this argument is more toward higher spec lasers. $AAOI is vertically integrated and has 300-400 mW capabilities, so they have the capability to shift attention to merchant lasers over supplying end-to-end optical transceivers. $SIVE is more pure play on this laser bottleneck, but they have the capabilities for 200mW + higher margin multiwavelength NPO/CPO lasers. I'd argue this is specifically the case for bottlenecks where demand imbalances are so deep (creating higher long term visibility, such as HBM). Whether it's large body substrates from $ATS that's bottlenecking Marvell + $AMD or lasers from $LITE that are sold out into 2029. or liquid transformers that have 4-5 year lead times. They they would still sell out of capacity even if overall demand decreased. If markets de-risked, it would make sense to hit optical module manufacturing players, maybe server rack assembly, to companies that still require heavy financing like Neoclouds. And obviously haircut growth valuations (but not to the point where demand collapses to 0). Yet we're seeing everything in AI trade is getting lumped up together as something that requires heavy financing + not profitable.
@BlueDuckCap

BDC on X

$STIM is up a lot. It should be up more. Neurostar back to growth +2%, call comments said 2027 will grow. New go to market is working - congrats to mgmt n phenomenal execution. Greenbrook accelerated. Still with lower occupancy on some units - lots of room to improve that. GAAP ebit profitability looks possible in 2027 (gross margins inflecting) and definitely in 2028. Cash flow+. Market still gives ZERO implied credit for the SOTP on Greenbrook even if we use a 5.5x GP multiple on Neurostar, below $BWAY at 7-8x. And then we have the $CMPS distribution partnership in 2027, even without which this is a $6-7 fair value sooner than later. They continue to execute on the growth story then this is $10+ in 12-24 months Not advice. We are long. That could change at any time.
@aleabitoreddit 1 click

Serenity on X

If a company is valued at $2B, has ~$1B in cash/inventory... And makes $354M FCF a quarter. Then returns 30-50% of FCF for dividends next year. I'd argue it's more of a matter of time before shareholder returns/fundamentals, (especially memory) overpower forced selling. But stock prices can look really dislocated from actual performance for periods of time, like now. Same with photonics, but that's more of a 2027-2028 growth type story with CPO + more optical content/xpu. Laser companies like $LITE, $AAOI, and potentially $SIVE depending on quals, would likely be printing few years after capacity expansion comes online. And it's already been largely funded... Lumentum with $NVDA + hyperscalers, AOI with $1.6B+ in ATMs, Sivers with 700M SEK from institutions. Compared to other sectors that still require a lot of capital for their buildouts.

Investor Letters

All letters

IEH Corporation: Research Note

IEH Corporation posted Q2 revenue growth of 51% to $10.7 million and a record $56 million backlog, led by defense and medical demand.

IEHC $78M
Atrium Research - Equity Research 1 click

Qure Anniversary Update

UniQure’s Huntington’s disease BLA has a May 1, 2027 priority-review date, with an FDA advisory committee expected in late first quarter.

QURE $1.7B
Triple S Special Situations Investing 2 clicks

Big Short: Fidelity & Guaranty

F&G’s main insurer held $66.5 billion of assets against $1.38 billion of statutory capital, while private credit, reinsurance dependence…

FG $3.1B
Mispriced Assets 4 clicks

Peloton: Beyond The Bike

Peloton’s connected-fitness subscribers fell 9% year over year to 2.475 million, with another high-single-digit holiday decline forecast as…

PTON $2.5B
TSOH Investment Research 3 clicks
MONOY · long

Monotaro CO LTD

MonotaRO, traded as MONOY in the U.S. and 3064 in Japan, is a Japanese MRO distributor recommended as a long.

MONOY $7.4B
Value Investors Club

Cat-Scratch Fervo

Fervo Energy raised $2 billion in its May IPO, then fell nearly 70% below issue price after a Morpheus short report, despite targeting 1 GW…

FRVO $3.8B
Doomberg 5 clicks

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

YouTube 4

Blogs 15

Seeking Alpha 85 of 289

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

376 firms

Sectors

Ordered by how often our editor reaches for them.